CagriSema (Cagrilintide + Semaglutide) (5 mg Vial) Dosage Protocol
CagriSema combines cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) in a single research formulation. Phase 2 trials demonstrate additive weight-loss effects beyond either component alone.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Titration (3 mL = ~3.33 mg/mL total)
Route: Subcutaneous injection. Frequency: Once weekly.
| Week/Phase | Dose per Peptide (mcg / mg) | Units (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) each | 15 units (0.15 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) each | 30 units (0.30 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) each | 60 units (0.60 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) each | 102 units (1.02 mL) |
| Week 17+ | 2400 mcg (2.4 mg) each | 144 units (1.44 mL) |
Note: Each dose delivers equivalent amounts of both cagrilintide and Semaglutide (e.g., 0.25 mg cagrilintide + 0.25 mg Semaglutide at Week 1). The 2.4 mg target mirrors clinical trial protocols.
Reconstitution Math
- Vial contents: 5 mg cagrilintide + 5 mg Semaglutide = 10 mg total blend
- Add: 3.0 mL bacteriostatic water
- Concentration: 10 mg ÷ 3.0 mL = 3.33 mg/mL total (1.67 mg/mL each peptide)
- Per unit (U‑100 syringe): 3333 mcg/mL × 0.01 mL = 33.3 mcg total per unit (16.7 mcg each peptide)
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; follow product-specific use-by instructions.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week weekly protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Cagrilintide + Semaglutide, 10 mg blend each) | 8 weeks ≈ 1 vial (~6 mg total used) 12 weeks ≈ 2 vials (~14 mg total used) 16 weeks ≈ 3 vials (~27.6 mg total used) |
| Insulin Syringes (U‑100) | Per week: 1 syringe (once weekly) 8 weeks: 8 syringes 12 weeks: 12 syringes 16 weeks: 16 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle 16 weeks (3 vials): 9 mL → 1 × 10 mL bottle |
| Alcohol Swabs | Per week: 2 swabs 8 weeks: 16 swabs 12 weeks: 24 swabs 16 weeks: 32 swabs → recommend 1 × 100‑count box |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
CagriSema combines two complementary mechanisms: cagrilintide acts on amylin receptors in the area postrema; semaglutide acts on GLP-1 receptors in the hypothalamus, gut, and pancreas. The two pathways together produce additive satiety and metabolic effects.
Potential Benefits & Side Effects
Potential Benefits
- Phase 2: 15.6% weight loss at 22 weeks vs 5–10% for either component alone.
- Complementary mechanisms — additive rather than redundant.
- Once-weekly dosing for both components.
Side Effect Profile
- Nausea (most common — additive between the two components).
- Vomiting and diarrhea during titration.
- Decreased appetite (intended).
Lifestyle Factors
- Hydrate well, prioritize protein, resistance train, smaller meals — same playbook as either component alone, but with potentially greater GI burden during titration.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm. Rotate sites weekly.
- 90° angle with short insulin needle.